Servier shared on LinkedIn:
“Our promising R&D pipeline – focused mainly on oncology and now neurology – includes 36 projects in clinical development and 24 research projects resulting from significant and continuous R&D investment.
To date, 50% of the Group’s research projects have the potential to become first-in-class treatments (a drug with a new and unique mechanism of action).
Learn more about Servier.”
More posts featuring Servier.
